BiotechTube
Home/Pipeline/KP-100IT (HGF protein)

KP-100IT (HGF protein)

Acute Spinal Cord Injury

Phase 3Completed Phase III single-arm study; additional study plan in progress

Key Facts

Indication
Acute Spinal Cord Injury
Phase
Phase 3
Status
Completed Phase III single-arm study; additional study plan in progress
Company
Kringle Pharma

About Kringle Pharma

Late-stage biotech developing HGF protein therapies for intractable neurological and regenerative diseases, with lead program in acute spinal cord injury.

View full company profile

Therapeutic Areas

NeuroscienceRegenerative MedicineRare Diseases

Other Acute Spinal Cord Injury Drugs

DrugCompanyPhase
AMFX-200SAmphix BioPreclinical
ExoPTENNurExone BiologicPreclinical
ES135Eusol BiotechPhase 3
OPC1Lineage Cell TherapeuticsPhase 1/2a